Dyslipidemia

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside increasing evidence for novel cholesterol-lowering medications, including PCSK9 inhibitors.

CHICAGO — A nurse-coordinated intensive intervention program emphasizing lifestyle and behavioral changes after ACS was associated with a 30% reduction in major adverse CV events for patients, primarily driven by a reduction in nonfatal MI.

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type 2 diabetes, study data show.

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting newer medications that could be added to statin therapy or used on patients intolerant to statins.

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment of CV risk.

Tracking lipid variability may be a reliable method of predicting dementia and cognitive decline among community-dwelling older adults, according to new research from Neurology.

Achieving obesity remission reduced children’s and teens’ risk for developing type 2 diabetes, hypertension and dyslipidemia in adulthood, according to findings from a study published in JAMA Pediatrics.

The American Heart Association has issued the 2025 update to its annual heart disease and stroke statistics report, detailing recent trends in CV-related morbidity and mortality.

CHICAGO — High year-to-year cholesterol variability was linked to increased risk for cognitive decline and dementia among older adults, a speaker reported.

BOSTON — Behavioral modification with diet and exercise demonstrated similar weight-loss benefits vs. other pharmaceutical and surgical approaches to obesity management, but patients must remain adherent, a speaker reported.